A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells

International Journal of Cancer

Volumn 130, Issue 6, 2012, Pages 1459-1469

  Lin, Li ^a,b   Benson Jr , Don M ^c   Deangelis, Stephanie ^a   Bakan, Courtney E ^c   Li, Pui Kai ^d   Li, Chenglong ^d   Lin, Jiayuh ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

multiple myeloma; small molecule inhibitors; STAT3

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BORTEZOMIB; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 6; LENALIDOMIDE; LLL 12; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT6 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTHRAQUINONES; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; HUMANS; INTERFERON-ALPHA; INTERFERON-GAMMA; INTERLEUKIN-4; INTERLEUKIN-6; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES;

EID: 84856099993     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26152     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
2. Buettner R, Mora LB, Jove R,. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-54. (Pubitemid 35177340)
3. Bromberg J, Darnell JE, Jr,. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19: 2468-73. (Pubitemid 30339202)
4. Turkson J, Jove R,. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000; 19: 6613-26. (Pubitemid 32197700)
5. Bowman T, Garcia R, Turkson J, Jove R,. STATs in oncogenesis. Oncogene 2000; 19: 2474-88. (Pubitemid 30339203)
6. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE, Jr,. Stat3 as an oncogene. Cell 1999; 98: 295-303. (Pubitemid 29380565)
7. Kaptein A, Paillard V, Saunders M,. Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem 1996; 271: 5961-4. (Pubitemid 26095392)
8. Faruqi T, Gomez D, Bustelo X, Bar-Sagi D, Reich N,. Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci USA 2001; 98: 9014-9. (Pubitemid 32743861)
9. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL,. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002; 21: 7611-8. (Pubitemid 35398808)
10. Yuan ZL, Guan YJ, Chatterjee D, Chin YE,. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307: 269-73. (Pubitemid 40116244)
11. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE,. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell cycle 2005; 4: 1131-3. (Pubitemid 41365374)
12. Schlessinger K, Levy DE,. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005; 65: 5828-34. (Pubitemid 40911187)
13. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R,. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-15. (Pubitemid 29077388)
14. Alas S, Bonavida B,. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-26. (Pubitemid 36109748)
15. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE, Inghirami G,. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11: 623-9. (Pubitemid 40868302)
16. Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, Yoshikawa K, Akira S, Takeda J,. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. Embo J 1999; 18: 4657-68. (Pubitemid 29415520)
17. Takeda K, Akira S,. Multi-functional roles of Stat3 revealed by conditional gene targeting. Arch Immunol Ther Exp (Warsz) 2001; 49: 279-83. (Pubitemid 33612108)
18. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr W, Jove R, Pardoll D, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-21. (Pubitemid 41752912)
19. Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, Lin J, Li PK,. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett 2008; 18: 391-5.
20. Song H, Wang R, Wang S, Lin J,. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005; 102: 4700-5. (Pubitemid 40471517)
21. Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, Cen L, Li C, et al. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppresive activity in human cancer cells. Neoplasia 2010; 12: 39-50.
22. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, et al. International uniform response criteria for multiple myeloma. leukemia 2006; 20: 1467-73. (Pubitemid 44264086)
23. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 2007; 26: 2435-44. (Pubitemid 46597261)
24. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder J, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman C,. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379: 645-8. (Pubitemid 26053453)
25. Schust J, Sperl B, Hollis A, Mayer TU, Berg T,. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006; 13: 1235-42. (Pubitemid 44750735)
26. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J,. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007; 104: 7391-6. (Pubitemid 47185916)
27. Shain K, Yarde D, Meads M, Huang M, Jove R, Hazlehurst L, Dalton W,. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009; 69: 1009-15.
28. Zhang Q, Wang HY, Woetmann A, Raghunath PN, Odum N, Wasik MA,. STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes. Blood 2006; 108: 1058-64. (Pubitemid 44154645)
29. Nielsen M, Kaestel C, Eriksen K, Woetmann A, Stokkedal T, Kaltoft K, Geisler C, Ropke C, Odum N,. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia 1999; 13: 735-8. (Pubitemid 29243625)
30. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC,. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 2007; 67: 9066-76. (Pubitemid 47535891)
31. Fuh B, Sobo M, Cen L, Josiah D, Hutzen B, Cisek K, Bhasin D, Regan N, Lin L, Chan C, Caldas H, DeAngelis S, et al. LLL-3 inhibits STAT3 activity, suppresses glioblastoma multiforme cell growth and prolongs survival in a mouse glioblastoma multiforme model. Br J Cancer 2009; 100: 106-12.
32. Shain K, Yarde D, Meads M, Huang M, Jove R, Hazlehurst L, Dalton W,. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009; 69: 1009-15.
33. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB,. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007; 109: 2293-302. (Pubitemid 46425866)
34. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB,. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103: 3175-84. (Pubitemid 38451696)
35. Bharti A, Donato N, Aggarwal B,. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863-71. (Pubitemid 37254592)
36. Yue P, Turkson J,. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs. 2009; 18: 45-56.
37. Ling X, Arlinghaus RB,. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005; 65: 2532-6. (Pubitemid 40490046)
38. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF,. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 2004; 3: 11-20. (Pubitemid 39193674)
39. Sledz CA, Williams BR,. RNA interference in biology and disease. Blood 2005; 106: 787-94. (Pubitemid 41076416)
40. Stein CA,. The experimental use of antisense oligonucleotides: a guide for the perplexed. J Clin Invest 2001; 108: 641-4. (Pubitemid 32906188)
41. Alas S, Bonavida B,. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9: 316-26. (Pubitemid 36109748)
42. van der Spek E, Bloem AC, Lokhorst HM, van Kessel B, Bogers-Boer L, van de Donk NW,. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma. Leuk Res 2009; 33: 100-8.
43. Park J, Ayyappan V, Bae EK, Lee C, Kim BS, Kim BK, Lee YY, Ahn KS, Yoon SS,. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2008; 2: 317-26.
44. Bill MA, Bakan C, Benson DM, Jr., Fuchs J, Young G, Lesinski GB,. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther 2009; 8: 2726-35.
45. Niu G, Heller R, Catlett-Falcone R, Coppola Jaroszeski M, Dalton W, Jove R, Yu H,. Gene therapy with dominant-negative STAT 3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999; 59: 5059-63. (Pubitemid 29503958)
46. Burke W, Jin X, Liu R, Huang M, Reynolds RK, Lin J,. Inhibition of constitutively active Stat3 pathway in ovarian and breast cancer cells. Oncogene 2001; 20: 7925-34. (Pubitemid 34002969)
47. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R,. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001; 98: 7319-24. (Pubitemid 32567946)
48. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, Niu G, Kay H, Mulé J, Kerr W, Jove R, Pardoll D, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314-21. (Pubitemid 41752912)